3Agid Y, Olanow CW, Mizuno Y. Levodopa: why the controversy? Lancet, 2002,360 : 575.
4Barone P. Clinical strategies to prevent and delay motor complications. Neurology, 2003, 61(Suppl 3) : s12- s16.
5Datla KP, Blunt SB, Dexter DT. Chronic L- DOPA administration is not toxic to the remaining dopaminergic nigrostriatal neurons, but instead may promote their functional recovery, in rats with partial 6- OHDA or FeCl3 nigrostriatal lesions. Mov Disord, 200
6Hubble J, Guarnieri M, Olanow CW. Effects of entacapone in Parkinson's disease patients without end of dose wearing off.Neurology, 2003, 60:289-290.
7Koller WC, Tse W. Unmet medical needs in Parkinson's disease. Neurology, 2004, 62(Suppl1): s1 - s8.
8Lewitt PA, Nyholm D. New developments in levodopa therapy.Neurology, 2004, 62(Suppl 1):s9-s16.
9Maratos EC, Jackson MJ, Pearce RK, et al. Botj short- and long - acting D - 1/D - 2 dopamine agonists induce less dyskinesia than L- DOPA in the MPTP - lesioned common marmoset (Callithrix jacchus). Exp Neurol, 2003, 179:90～ 102.
10Mytilineou C, Walker RH, Jno Baptiste R, et al. Levodopa is toxic to dopamine neurons in an in vitro but not in an in vivo model of oxidative stress. J Pharmacol Exp Ther, 2003, 304:792-800.
